|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
![]() |
|
||||||||||||
|
|
|
||||||||||||
|
|
|
||||||||||||
|
|
|
![]() |
|||||||||||
|
|
|||||||||||||
|
|
|
|
|
|
|
|
|||||||
|
|
|||||||||||||
|
|
![]() |
||||||||||||
|
|
|
||||||||||||
| |
SELECTED PUBLICATIONSOn the technology by the scientists involved in Lauras HIV:Protein kinase A type I antagonist restores immune responses of T cells
from HIV-infected patients, FASEB J., 1998 Additive effects of IL-2 and protein kinase A type I antagonist on function of T cells from HIV-infected patients on HAART.AIDS, 13:F109-14, 1999 Cytokine networks are pre-activated in T cells from HIV-infected patients on HAART and are under the control of cAMP.AIDS, 2004 and Editorial Comment in same issue of AIDS CVI (Common Variable Immunodeficiency):Increased Activation of Protein Kinase A Type I Contributes to the T Cell Deficiency
in Common Impaired secretion of IL-10 by T cells from patients with common variable immunodeficiency – involvement of protein kinase A Type I. J. Immunol., 2003 Mouse model disease (MAIDS):Increased cAMP levels and protein kinase (PKA) type I activation in CD4+
T cells and B cells contribute to retrovirus-induced immunodeficiency
of mice (MAIDS): a useful in vivo model for drug testing, FASEB J., 2001 Targeting COX-2:Cyclooxygenase type 2-dependent prostaglandin E2 secretion is involved in retrovirus-induced T cell dysfunction in mice. Biochem. J., 2004. Treatment with type-2 selective and non-selective cyclooxygenase inhibitors improves T-cell proliferation in HIV-infected patients on highly active antiretroviral therapy.n. AIDS, 2004. Immune modulatory effects of cyclooxygenase type 2 inhibitors in HIV patients on combination antiretroviral treatment. AIDS, 2006. Molecular mechanisms and scientific basis:Foxp3+ adaptive regulatory T cells express cycloxygenase type 2 and suppress T effector cells by a prostaglandin E2-dependent mechanism. J. Immunol, 2006. The cyclic AMP-Epac1-Rap1 pathway is dissociated from regulation of effector functions in monocytes but acquires immunoregulatory function in mature macrophages. J. Immunol, 2006. T cell receptor and CD28-mediated recruitment of phosphodiesterase 4 to lipid rafts potentiates T cell receptor signaling. J. Immunol., 2004. Knockdown of C-terminal Src kinase by siRNA-mediated RNA interference augments T cell receptor signaling in mature T cells. Eur. J. Immunol. Combined spatial and enzymatic regulation of Csk by cAMP and protein kinase a inhibits T cell receptor signaling. J Biol Chem. 2003 Protein kinase A intersects Src signaling in detergent membrane microdomains. J. Biol. Chem., 2003. A winged helix forkhead (FOXD2) tunes sensitivity to cAMP in T lymphocytes through regulation of cAMP-dependent protein kinase RIα. J. Biol. Chem., 2003. Inhibition of antigen specific T cell proliferation and cytokine production by PKA type I. J. Immunol. 2002 Activation of the COOH-terminal Src kinase (Csk) by cAMP-dependent Protein Kinase Inhibits Signaling through the T Cell Receptor, Journal of Experimental Medicine, 2001 http://www.jem.org/cgi/content/full/193/4/497 Release from tonic inhibition of T cell activation through transient
displacement of c-terminal Src kinase (Csk) from lipid rafts. J.Biol.
Chem., in press- accelerated publication, 2001 Selective Activation of cAMP-dependent Protein Kinase Type I Inhibits
Rat Natural Killer Cell Cytotoxicity, Journal of Biological Chemistry,
1997 Cyclic AMP-dependent protein kinase in human B cells. Localization of
the regulatory subunit RIa with the B cell antigen receptor during B cell
activation. European Journal of Immunolology, 26:1290-1296, 1996 Location of cAMP-dependent protein kinase type I with the TCR/CD3 complex.
Science, 263:84-87, 1994 Reviews:Role of cAMP phosphodiesterase type 4 in regulation of T cell function. Crit. Rev. Immunol., 2006 Negative regulation of T-cell receptor activation by the cAMP-PKA-Csk signalling pathway in T-cell lipid rafts. Front. Biosci., 2006. The molecular machinery for cAMP-dependent immunomodulation in T cells. Biochem. Soc. Transact., 2006. Localised effects of cAMP mediated by distinct routes of Protein Kinase A. Physiological Rev.2004. Positive and negative regulation of T cell activation by kinases and phosphatases. Biochem. J., 2003. Protein kinase A type I as a potential target for therapeutic intervention. Drug News Perspect 13: 12-18, 2000 Molecular mechanisms for protein kinase A-mediated inhibition of immune function. Cell. Signalling, 2001 Specificity in the cAMP/PKA signaling pathway. Differential expression, regulation, and subcellular localization of subunits of PKA, Frontiers in Bioscience, 2000 |
||||||||||||
|
|
|||||||||||||